Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights

Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023Celyad Oncology has received approximately EUR 9.8m in private placement commitments from historical shareholdersEncouraging progress in multiplex shRNA platform development, which allows now targeting of up to four genes simultaneously, were...

Related Keywords

Boston ,Massachusetts ,United States ,Mont Saint Guibert ,Waals Gewest ,Belgium ,Walloon Region ,London ,City Of ,United Kingdom ,Parc ,Region Flamande ,American ,David Georges ,Georges Rawadi ,Celdara Medical ,World Oncology Cell Therapy Congress ,Society For Immunotherapy Of Cancer ,Company Or Celyad Oncology ,Dartmouth College ,Business Development Intellectual Property ,Exchange Commission ,International Conference On Lymphocyte Engineering ,Chief Executive Officer ,Regulatory News ,Celyad Oncology ,Chief Executive ,Vice President Business Development ,Intellectual Property ,American Depositary Shares ,Nasdaq Global ,Euronext Brussels ,Lancet Haematology Journal ,Immuno Oncology Summit Europe ,Axis Parc ,International Conference ,Lymphocyte Engineering ,San Diego ,Belgium Fixed ,Belgium Mobile ,Private Securities Litigation Reform Act ,Annual Report ,Consolidated Statement ,Comprehensive Income ,Financial Position ,